Parkman Healthcare Partners’s Apogee Therapeutics APGE Stock Holding History

Parkman Healthcare Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.54M	Sell	77,686 -52,383	-40%	-$3.8M	0.67%	49
2025 Q4	$9.82M	Buy	130,069 +24,238	+23%	+$1.53M	0.93%	40
2025 Q3	$4.2M	Buy	105,831 +50,427	+91%	+$1.93M	0.44%	66
2025 Q2	$2.41M	Buy	55,404 +8,741	+19%	+$333K	0.28%	79
2025 Q1	$1.74M	Sell	46,663 -38,337	-45%	-$1.48M	0.21%	78
2024 Q4	$3.85M	Buy	+85,000	New	+$4.33M	0.51%	53

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Parkman Healthcare Partners's APGE Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Apogee Therapeutics (APGE) stake by 40% in Q1 2026, selling an estimated $3.8M and leaving 77,686 shares worth $6.54M. The position accounts for 0.67% of the portfolio, ranked #49.

Parkman Healthcare Partners first reported a position in APGE in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.82M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Parkman Healthcare Partners held 77,686 shares of Apogee Therapeutics worth $6.54M as of Q1 2026.
Parkman Healthcare Partners sold 52,383 Apogee Therapeutics shares in Q1 2026, an estimated $3.8M.
Apogee Therapeutics made up 0.67% of Parkman Healthcare Partners's portfolio in Q1 2026, its #49 holding.
Parkman Healthcare Partners first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 6 quarters since.
Parkman Healthcare Partners's Apogee Therapeutics position peaked at $9.82M in Q4 2025.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.